[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse XRCC5

Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, nucleolus Chromosome
Domain PF02735 Ku70/Ku80 beta-barrel domain
PF03730 Ku70/Ku80 C-terminal arm
PF03731 Ku70/Ku80 N-terminal alpha/beta domain
PF08785 Ku C terminal domain like
Function

Single-stranded DNA-dependent ATP-dependent helicase. Has a role in chromosome translocation. The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' direction. Binding to DNA may be mediated by XRCC6. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold. The XRCC5/6 dimer is probably involved in stabilizing broken DNA ends and bringing them together (PubMed:12145306, PubMed:20383123, PubMed:7957065, PubMed:8621488). The assembly of the DNA-PK complex to DNA ends is required for the NHEJ ligation step. In association with NAA15, the XRCC5/6 dimer binds to the osteocalcin promoter and activates osteocalcin expression (PubMed:20383123). The XRCC5/6 dimer probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks. XRCC5 probably acts as the catalytic subunit of 5'-dRP activity, and allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined. The XRCC5/6 dimer together with APEX1 acts as a negative regulator of transcription (PubMed:8621488). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway.

> Gene Ontology
 
Biological Process GO:0000723 telomere maintenance
GO:0000726 non-recombinational repair
GO:0001101 response to acid chemical
GO:0001819 positive regulation of cytokine production
GO:0002244 hematopoietic progenitor cell differentiation
GO:0006302 double-strand break repair
GO:0006303 double-strand break repair via nonhomologous end joining
GO:0006310 DNA recombination
GO:0006970 response to osmotic stress
GO:0006972 hyperosmotic response
GO:0009314 response to radiation
GO:0009651 response to salt stress
GO:0010165 response to X-ray
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010639 negative regulation of organelle organization
GO:0010720 positive regulation of cell development
GO:0019042 viral latency
GO:0019043 establishment of viral latency
GO:0032200 telomere organization
GO:0032204 regulation of telomere maintenance
GO:0032205 negative regulation of telomere maintenance
GO:0032392 DNA geometric change
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032508 DNA duplex unwinding
GO:0032606 type I interferon production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0033002 muscle cell proliferation
GO:0033044 regulation of chromosome organization
GO:0042493 response to drug
GO:0042538 hyperosmotic salinity response
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048863 stem cell differentiation
GO:0050769 positive regulation of neurogenesis
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051962 positive regulation of nervous system development
GO:0060218 hematopoietic stem cell differentiation
GO:0060249 anatomical structure homeostasis
GO:0070542 response to fatty acid
GO:0071103 DNA conformation change
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071396 cellular response to lipid
GO:0071398 cellular response to fatty acid
GO:0071470 cellular response to osmotic stress
GO:0071472 cellular response to salt stress
GO:0071474 cellular hyperosmotic response
GO:0071475 cellular hyperosmotic salinity response
GO:0071478 cellular response to radiation
GO:0071479 cellular response to ionizing radiation
GO:0071480 cellular response to gamma radiation
GO:0071481 cellular response to X-ray
GO:0075713 establishment of integrated proviral latency
GO:0090656 t-circle formation
GO:1904429 regulation of t-circle formation
GO:1904430 negative regulation of t-circle formation
GO:2001251 negative regulation of chromosome organization
Molecular Function GO:0003678 DNA helicase activity
GO:0003684 damaged DNA binding
GO:0003691 double-stranded telomeric DNA binding
GO:0004003 ATP-dependent DNA helicase activity
GO:0004386 helicase activity
GO:0008022 protein C-terminus binding
GO:0008026 ATP-dependent helicase activity
GO:0008094 DNA-dependent ATPase activity
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0016887 ATPase activity
GO:0031625 ubiquitin protein ligase binding
GO:0042162 telomeric DNA binding
GO:0042623 ATPase activity, coupled
GO:0044389 ubiquitin-like protein ligase binding
GO:0051575 5'-deoxyribose-5-phosphate lyase activity
GO:0070035 purine NTP-dependent helicase activity
Cellular Component GO:0000781 chromosome, telomeric region
GO:0000782 telomere cap complex
GO:0000783 nuclear telomere cap complex
GO:0000784 nuclear chromosome, telomeric region
GO:0032993 protein-DNA complex
GO:0043564 Ku70:Ku80 complex
GO:0044454 nuclear chromosome part
GO:0070419 nonhomologous end joining complex
GO:0098687 chromosomal region
GO:1990391 DNA repair complex
> KEGG and Reactome Pathway
 
KEGG hsa03450 Non-homologous end-joining
Reactome R-HSA-164843: 2-LTR circle formation
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-1643685: Disease
R-HSA-162594: Early Phase of HIV Life Cycle
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-3270619: IRF3-mediated induction of type I IFN
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-162592: Integration of provirus
R-HSA-6798695: Neutrophil degranulation
R-HSA-5693571: Nonhomologous End-Joining (NHEJ)
R-HSA-1834941: STING mediated induction of host immune responses
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between XRCC5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of XRCC5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.46; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of XRCC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1560.356
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1290.966
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1780.936
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1410.695
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1480.952
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5080.874
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0220.966
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1290.957
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1870.944
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2010.919
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0770.98
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0860.109
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of XRCC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of XRCC5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of XRCC5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by XRCC5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of XRCC5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of XRCC5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between XRCC5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolXRCC5
NameX-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
Aliases KU80; KARP-1; Ku86; KUB2; Ku autoantigen, 80kDa; X-ray repair complementing defective repair in Chinese hams ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting XRCC5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.